Matrix Metalloproteinase-13 (MMP-13): A proposed Tumor Marker in Breast Carcinoma

B, Ahmed B.; Zakaria, N.M; Mohamed, D. A.; Omar, A. R; Seif, A. M

doi:10.21608/jsrs.2019.57635

Matrix Metalloproteinase-13 (MMP-13): A proposed Tumor Marker in Breast Carcinoma

Document Type : Original Article

Authors

¹ ,Microbiology Department, Faculty of Science, Ain Shams University.

² , Clinical Pathology Department, Faculty of Medicine, Ain Shams University.

³ Clinical Pathology Department, Faculty of Medicine, Ain Shams University. Abstract:

⁴ Microbiology Department, Faculty of Science, Ain Shams University.

10.21608/jsrs.2019.57635

Abstract

Breast cancer is estimated to account for 31% new onset female cancers. Matrix metalloproteinases (MMPs) are extracellular zinc-dependent endopeptidases involved in the degradation and remodeling of extracellular matrix in physiological and pathological processes. In this study, we aimed to evaluate the use of matrix metalloproteinase-13 (MMP-13) as a potential tumor marker in breast cancer and we also aimed to investigate the role of infection as a cause of carcinogenesis by estimating the incidence of anti-cytomegalovirus IgG antibodies in breast cancer patients.
Subjects and Methods:
Serum CA15.3, anti-CMV IgG and MMP-13 were measured in 50 breast cancer female patients, 20 female patients with fibroadenoma of breast and 20 healthy age-matched female volunteers.
Results:
MMP-13 levels showed no significant difference between breast cancer patients and controls; on the other hand MMP-13 levels were significantly higher in fibroadenoma patients compared to controls. CA15.3 levels were significantly higher in breast cancer cases compared to both fibroadenoma and healthy controls.
Conclusion:
The results of this study show that MMP-13 level is highest among control group, while fibroadenoma group had the lowest MMP-13 level. CA15.3 is still the most useful serum tumor marker in patients with breast cancer.